Verosudil

Verosudil (AR-12286) is a drug which acts as a potent and selective inhibitor of the enzyme Rho kinase, and has been investigated for the treatment of glaucoma.[1][2]

Verosudil
Identifiers
  • 2-(dimethylamino)-N-(1-oxo-2H-isoquinolin-6-yl)-2-thiophen-3-ylacetamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC17H17N3O2S
Molar mass327.40 g·mol−1
3D model (JSmol)
  • CN(C)C(C1=CSC=C1)C(=O)NC2=CC3=C(C=C2)C(=O)NC=C3
  • InChI=1S/C17H17N3O2S/c1-20(2)15(12-6-8-23-10-12)17(22)19-13-3-4-14-11(9-13)5-7-18-16(14)21/h3-10,15H,1-2H3,(H,18,21)(H,19,22)
  • Key:VDYRZXYYQMMFJW-UHFFFAOYSA-N

See also

References
  1. Williams RD, Novack GD, van Haarlem T, Kopczynski C (November 2011). "Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension". American Journal of Ophthalmology. 152 (5): 834–41.e1. doi:10.1016/j.ajo.2011.04.012. PMID 21794845.
  2. Skaat A, Jasien JV, Ritch R (September 2016). "Efficacy of Topically Administered Rho-Kinase Inhibitor AR-12286 in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma". Journal of Glaucoma. 25 (9): e807-14. doi:10.1097/IJG.0000000000000508. PMID 27552517. S2CID 2663391.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.